Becton, Dickinson and Company
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Becton, Dickinson and Company (BD) manufactures and distributes a broad range of medical technologies, devices, laboratory equipment, and diagnostic products to healthcare providers, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and governments worldwide. The company operates through three primary segments: BD Medical, which provides medication delivery solutions including peripheral intravenous and advanced peripheral catheters, hypodermic syringes and needles, prefilled syringes, needle-free IV connectors, closed-system drug transfer devices, infusion pumps such as the BD Alaris system, and medication management solutions like the BD Pyxis automated dispensing cabinets; BD Life Sciences, which offers preanalytical systems for specimen collection and management such as BD Vacutainer tubes, flow cytometry instruments and reagents for immunology research, multiomics tools, microbiology and molecular diagnostics, lab automation, and informatics solutions; and BD Interventional, which delivers vascular access products including venous stents and atherectomy devices, urology and critical care solutions such as PureWick urine management systems and CentraVena central catheters, surgical instruments, infection prevention products, hernia repair meshes, and biosurgery grafts. BD maintains manufacturing and distribution facilities across more than 50 countries, including the United States, Europe, Asia-Pacific, Latin America, and others, with approximately 70,000 employees supporting global operations. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD advances clinical therapy and processes through ongoing innovation. Recent developments include the July 2025 agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a $17.5 billion Reverse Morris Trust transaction, expected to close in late 2026, enabling BD to sharpen focus on medical technology while receiving about $4 billion in cash for share repurchases and debt reduction; the October 2025 launch of the AI-enabled BD Incada Connected Care Platform integrated with the next-generation BD Pyxis Pro dispensing solution for enterprise-wide medication data analytics; the September 2025 pharmacy automation partnership with Henry Ford Health utilizing BD Rowa Vmax for robotic prescription handling; FDA clearance and planned launch of the CentraVena rapid insertion central catheter entering the $500 million market; introduction of the PureWick Portable Collection System for mobile urine management; and expanded U.S. manufacturing investments in syringes, needles, and IV catheters announced in January 2025.
Becton, Dickinson: Value Or Overvalued Even Now?
What's Going On With Becton Dickinson Stock Tuesday?
Becton, Dickinson and Company: A Q1 2026 Earnings And Post Spin-Off Examination
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings
How To Earn $500 A Month From Becton Dickinson Stock Ahead Of Q1 Earnings
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst
Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal
Becton, Dickinson and Company: A Dividend Idea With Diverse Medtech Portfolio To Meet Future Demand
Becton Dickinson's CFO to depart
Becton, Dickinson: Great Time To Buy This Dividend Aristocrat
Becton Dickinson Q3 Beats Estimates On Medical Device Boom
Becton Dickinson joins peer in raising annual profit forecast after results beat
Becton Dickinson gets its spinoff deal, but the stock is still falling
Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales
Cramer's Stop Trading: Becton Dickinson
Medical device maker Becton Dickinson cuts 2025 profit forecast on potential tariff hit